SCHEMBL21998080

SCHEMBL21998080

CS(=O)(=O)OC1COC(Cc2cccc(C(=O)O)c2)OC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.40
MRGPRX4 Q96LA9 10/20 0.39
TP53 P04637 2/20 0.39
PKM P14618 2/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
GFER P55789 1/20 0.38
PAX8 Q06710 1/20 0.38
KLF5 Q13887 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
HIF1A Q16665 1/20 0.38
PPM1D O15297 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3150745 0.79 FOLH1 (0.54) FOLH1MRGPRX4CYP2D6CYP2C9HIF1A
SCHEMBL23808026 0.74 CHRNB2 (0.42) FOLH1NPC1POLB
SCHEMBL21997201 0.74 CHRNB2 (0.42) FOLH1NPC1POLB
SCHEMBL4446212 0.73 FOLH1 (0.54) FOLH1MRGPRX4CYP2D6CYP2C9HIF1A
SCHEMBL35452 0.70 FOLH1 (0.58) FOLH1MRGPRX4TP53PKMNFKB1
SCHEMBL31401245 0.70 FOLH1 (0.58) FOLH1MRGPRX4TP53PKMNFKB1
SCHEMBL29668711 0.68 FOLH1 (0.51) FOLH1MRGPRX4CYP2D6CYP2C9HIF1A
SCHEMBL14165133 0.66 KMT2A (0.44) L3MBTL1
SCHEMBL39776 0.66 FOLH1 (0.45) FOLH1MRGPRX4TP53PKMNFKB1
SCHEMBL6011976 0.66 FOLH1 (0.56) FOLH1MRGPRX4TP53PKMNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 EP disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 US disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 FOLH1 2319/4885MRGPRX4 1869/4885TP53 1474/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 FOLH1 2319/4885MRGPRX4 1869/4885TP53 1474/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 FOLH1 2319/4885MRGPRX4 1869/4885TP53 1474/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 FOLH1 2319/4885MRGPRX4 1869/4885TP53 1474/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 FOLH1 2319/4885MRGPRX4 1869/4885TP53 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.